Evaluation of homoharringtonine efficacy in the treatment of squamous cell carcinoma of the head and neck: a phase II Illinois cancer council study

Eighteen patients entered this study of the efficacy of homoharringtonine (HHT) treatment in advanced squamous cell carcinoma of the head and neck (SCCHN). Seventeen eligible patients received at least one day of the first 5-day cycle of HHT (4.0 mg/m2/day) by continuous IV infusion. Cycles were sch...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Investigational new drugs 1989-07, Vol.7 (2-3), p.269-273
Hauptverfasser:	RUNGE-MORRIS, M. A, KIES, M. S, VOKES, E, BLOUGH, R, WEIDNER, L, KNOP, R, ROWLAND, K
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Alkaloids - therapeutic use Antineoplastic agents Biological and medical sciences Carcinoma, Squamous Cell - drug therapy Chemotherapy Drug Evaluation Female Harringtonines - administration & dosage Harringtonines - adverse effects Harringtonines - therapeutic use Head and Neck Neoplasms - drug therapy Hematologic Diseases - chemically induced Humans Infusions, Intravenous Male Medical sciences Middle Aged Pharmacology. Drug treatments
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Eighteen patients entered this study of the efficacy of homoharringtonine (HHT) treatment in advanced squamous cell carcinoma of the head and neck (SCCHN). Seventeen eligible patients received at least one day of the first 5-day cycle of HHT (4.0 mg/m2/day) by continuous IV infusion. Cycles were scheduled to repeat every 28 days. The major severe toxicities encountered were hypotension and myelosuppression. There was one drug-related death. Fourteen patients were evaluable for response, and no patient exhibited an objective response to treatment with HHT.
ISSN:	0167-6997 1573-0646
DOI:	10.1007/BF00170872